Travere Therapeutics (NASDAQ:TVTX) Receives Buy Rating from HC Wainwright

HC Wainwright reissued their buy rating on shares of Travere Therapeutics (NASDAQ:TVTX) in a report published on Tuesday morning,Benzinga reports. They currently have a $47.00 price objective on the stock.

Other research analysts have also issued reports about the stock. Wall Street Zen lowered shares of Travere Therapeutics from a “strong-buy” rating to a “buy” rating in a research note on Saturday, February 21st. Citigroup boosted their target price on shares of Travere Therapeutics from $48.00 to $53.00 and gave the company a “buy” rating in a research note on Tuesday. Weiss Ratings reissued a “sell (e+)” rating on shares of Travere Therapeutics in a research note on Wednesday, January 21st. Piper Sandler boosted their target price on shares of Travere Therapeutics from $35.00 to $38.00 and gave the company a “neutral” rating in a research note on Friday, February 6th. Finally, Guggenheim reissued a “buy” rating and set a $49.00 target price on shares of Travere Therapeutics in a research note on Wednesday, January 14th. Eleven investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $42.50.

Travere Therapeutics Trading Up 37.2%

NASDAQ TVTX opened at $42.13 on Tuesday. Travere Therapeutics has a one year low of $13.88 and a one year high of $43.31. The company has a 50-day simple moving average of $29.38 and a 200-day simple moving average of $31.30. The company has a debt-to-equity ratio of 2.71, a quick ratio of 2.70 and a current ratio of 2.74. The firm has a market capitalization of $3.89 billion, a PE ratio of -140.43 and a beta of 0.86.

Insider Buying and Selling

In other news, insider Jula Inrig sold 1,779 shares of the company’s stock in a transaction that occurred on Wednesday, February 4th. The shares were sold at an average price of $32.21, for a total value of $57,301.59. Following the completion of the sale, the insider directly owned 105,706 shares of the company’s stock, valued at approximately $3,404,790.26. This represents a 1.66% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider Elizabeth E. Reed sold 10,000 shares of the company’s stock in a transaction that occurred on Wednesday, April 1st. The stock was sold at an average price of $30.00, for a total transaction of $300,000.00. Following the completion of the sale, the insider directly owned 105,211 shares of the company’s stock, valued at approximately $3,156,330. This represents a 8.68% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders sold 312,067 shares of company stock worth $9,755,570. Company insiders own 4.06% of the company’s stock.

Institutional Trading of Travere Therapeutics

Institutional investors have recently made changes to their positions in the stock. Raymond James Financial Inc. acquired a new stake in shares of Travere Therapeutics in the 2nd quarter worth approximately $33,000. First Horizon Corp acquired a new stake in shares of Travere Therapeutics in the 3rd quarter worth approximately $36,000. State of Wyoming acquired a new stake in shares of Travere Therapeutics in the 4th quarter worth approximately $37,000. Torren Management LLC acquired a new stake in shares of Travere Therapeutics in the 4th quarter worth approximately $38,000. Finally, Comerica Bank lifted its stake in shares of Travere Therapeutics by 77.5% in the 4th quarter. Comerica Bank now owns 1,127 shares of the company’s stock worth $43,000 after acquiring an additional 492 shares during the period.

Trending Headlines about Travere Therapeutics

Here are the key news stories impacting Travere Therapeutics this week:

• Positive Sentiment: U.S. FDA expanded / granted full approval of FILSPARI (sparsentan) as the first approved medicine for FSGS — the company’s lead commercial asset and the main fundamental catalyst behind today’s rally. Business Wire: FILSPARI approval Reuters: FDA expands approval
• Positive Sentiment: Multiple brokerages raised ratings and price targets after the approval: Canaccord raised its PT to $56 (buy), Guggenheim to $54 (buy), Piper Sandler upgraded to overweight with a $49 PT, Wedbush raised its PT to $44 (outperform), and HC Wainwright reaffirmed buy at $47 — collectively signaling stronger sell-side conviction and added buy-side interest. Benzinga: analyst moves
• Positive Sentiment: Unusually large call-option activity: traders bought ~21,305 calls on Monday (≈552% above normal), indicating speculative/hedged bullish positioning ahead of or on the news. This options flow likely amplified intraday upside. (No single-source link provided in feed.)
• Neutral Sentiment: Trading was temporarily halted for TVTX with a “news pending” halt prior to the announcement — a procedural move that often precedes major company or regulatory news and can concentrate volume when trading resumes.

Travere Therapeutics Company Profile

Travere Therapeutics, Inc (NASDAQ: TVTX) is a biopharmaceutical company headquartered in San Diego, California, dedicated to the development and commercialization of therapies for rare kidney and genetic disorders. The company’s mission is to address unmet needs in conditions with limited treatment options by focusing on diseases that affect small patient populations. Travere combines research, development and commercial capabilities to bring innovative medicines to market.

The company’s lead product is sparsentan, a dual endothelin angiotensin receptor antagonist that has received accelerated approval from the U.S.